PDS Biotech Announces Presentation of PDS0101 Data at the 2022 Multidisciplinary Head and Neck Cancers Symposium
January 12, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy
January 10, 2022 07:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotechnology to Present at H.C. Wainwright Bioconnect Virtual Conference
January 05, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
December 23, 2021 16:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...
PDS Biotechnology Expands VERSATILE-002 study of PDS0101 and KEYTRUDA® in Advanced Head and Neck Cancer to Include Patients Who Have Failed Prior Treatment with Checkpoint Inhibitors
June 03, 2021 08:53 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...
PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting
May 20, 2021 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results
May 13, 2021 07:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., May 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...
PDS Biotechnology Announces Participation in Noble Capital Markets C-Suite Interview Series
May 12, 2021 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...